Inactive Instrument

Press Releases Acasti Pharma Inc. Toronto S.E.

Equities

ACST

CA00430K8730

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights	Feb. 12	AQ
Acasti: Fiscal Q3 Earnings Snapshot	Feb. 12	AQ
Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial	Feb. 01	AQ
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024	Dec. 13	AQ
Brain Hemorrhage Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	Nov. 14	AQ
Acasti: Fiscal Q2 Earnings Snapshot	Nov. 13	AQ
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights	Nov. 13	AQ
Aker BioMarine acquires patents, equipment, and scientific data from Acasti Pharma Inc	23-10-24	AQ
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial	23-10-23	AQ
Acasti Pharma to Host KOL Event on GTX-104, A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage	23-10-05	AQ
Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)	23-10-04	AQ
Acasti Announces $7.5 Million Private Placement Equity Financing	23-09-26	AQ
Acasti to Participate in the H.C. Wainwright Global Investment Conference	23-09-06	AQ
Acasti Announces First Quarter 2024 Financial Results and Business Highlights	23-08-14	AQ
Acasti: Fiscal Q1 Earnings Snapshot	23-08-11	AQ
Acasti Announces First Quarter 2024 Financial Results and Business Highlights	23-08-11	AQ
Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting	23-08-09	AQ
Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients	23-07-10	PR
Acasti Pharma Announces 1-for-6 Reverse Stock Split	23-07-07	PR
Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023	23-07-05	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Acasti Pharma Inc. Toronto S.E.

Equities

ACST

CA00430K8730

Press Releases

Filters